NEW YORK – The National Institute for Health and Care Excellence (NICE) is recommending Novartis' Kisqali (ribociclib) plus an aromatase inhibitor for certain patients with early-stage breast cancer ...

A pilot study using neuropsychological testing from the Arimidex, Tamoxifen ... [13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration.

While tamoxifen blocks oestrogen's effects on cancer cells, the new drug, called an aromatase inhibitor, shuts down the body's oestrogen supply altogether. Arimidex is currently licensed for ...

A Comprehensive Guide to Aromatase Inhibitors: Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know that understanding your ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

A Comprehensive Guide to Aromatase Inhibitors: Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know that understanding your ...

It is used in combination with an aromatase inhibitor as a first-line endocrine therapy for postmenopausal women or men or with fulvestrant for patients whose disease has progressed after ...

It is taken in pill form twice a day, in combination with an aromatase inhibitor, a hormone therapy that reduces estrogen levels in the body. Clinical evidence shows that combining ribociclib with ...

Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrophil serine proteases, key mediators of neutrophilic inflammation. In a phase 3, double-blind trial ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

pharmaphorum speaks with Steven Davis of AstraZeneca on how the first year of its first direct-to-patient program - ARIMIDEX Direct has been. A year ago, AstraZeneca announced its first direct-to ...